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osting by EAbstract Imaging is one of the most important accomplishments of medicine during the last
1000 years. The contribution of modern imaging to progress in the delivery of health care is unques-
tioned. However, we need to reﬁne our use of imaging, limiting its use to those occasions when it
can contribute directly or indirectly to improving and lengthening the lives of patients. Technology
prowess in imaging alone is not sufﬁcient to deliver value to individuals or to society. Continued
investment in imaging technology requires critical appraisal of its use in clinical decision making
and patient outcomes.
ª 2010 King Saud University. All rights reserved.At the beginning of the 21st century, the editors of the New
England Journal named medical imaging as one of the 10 most
important developments in all of medicine during the preced-
ing 1000 years (Anon., 2000). Imaging of the cardiovascular
system is barely a century old, beginning with the discovery
of X-rays in the early 20th century. Mason Sones’ pursuit of
coronary arteriography in the 1960s (Sones and Shirey, 1962)
led directly to the development of coronary bypass surgery
and percutaneous coronary intervention and thrombolytic
therapy, fundamentally impacting the practice of cardiology
around the world. Echocardiography (Edler, 1966; Feigen-
baum et al., 1965) and nuclear cardiology (Wagner, 1974), also
introduced to clinical cardiology in the 1960s, revolutionized(S. Wann).
ity. All rights reserved. Peer-
d University.
lsevierthe evaluation of structural heart disease and myocardial ische-
mia. As these methods continue to be reﬁned and popularized
additional imaging methods including cardiac magnetic reso-
nance imaging1 and cardiovascular computed tomographic
angiography (Min et al., 2010) have vastly improved our abil-
ity to image various manifestations of cardiovascular disease
with ever increasing sophistication.
Cardiovascular disease is the most common cause of death
worldwide, and an important focus for medical imaging. Our
understanding of the fundamental pathophysiologic mecha-
nisms underlying acute coronary syndrome and myocardial
infarction continues to evolve in concert with the development
of new and better means for assessing these abnormalities.
Imaging has had a central role in improving our ability to rec-
ognize, characterize and successfully treat coronary artery dis-
ease. Cardiac catheterization with coronary arteriography and
adjunctive techniques including intravascular ultrasound, ocu-
lar coherence tomography, and measurement of local temper-
ature and PH within the heart have not only allowed
development of the entire ﬁeld of surgical and percutaneous
coronary revascularization and thrombolytic therapy, but is
leading to an improved understanding of the mechanisms of1 CMR= Pennel review.
122 S. Wann, J. Tunioischemic heart disease and development of better preventive
and pharmacologic strategies.
The diagnostic and prognostic accuracy of ECG stress test-
ing was vastly improved by the addition of concomitant nucle-
ar or ultrasound imaging. The use of metabolically active
tracers allowed better understanding of coronary artery dis-
ease at the cellular level, just as sophisticated ultrasound
and magnetic resonance tools have revealed many of the
mechanical, structural and hemodynamic alterations resulting
from acute and chronic macro- as well as micro-vascular cor-
onary syndromes. Imaging techniques can be used to study
coronary arterial plaques. These plaques have thrombogenic
potential and are manifestations of atherosclerosis, a systemic
disease affecting the vessel wall which is generally believed to
be the primary cause of many of the other myriad manifesta-
tions of coronary artery disease (Fayad et al., 2002; Ambrose,
2008). Non-invasive imaging holds the promise to not only
identify ﬂow limiting coronary stenosis (Meijboom et al.,
2008), but to also detect calciﬁed and non-calciﬁed plaque,
measure atherosclerotic plaque burden and its response to
treatment, and to differentiate stable plaques from those
which are prone to rupture (Kitagawa et al., 2009; Takumi
et al., 2007). These expectations have not yet been met (Nis-
sen, 2008).
Technologic progress in computed tomography has led to
the ability to non-invasively visualize the epicardial coronary
arteries with spatial and temporal resolution approaching
that of invasive angiography. However, we know that high
resolution angiography alone is often insufﬁcient to differen-
tiate ﬂow limiting from non-ﬂow limiting stenosis (Tonino
et al., 2009; Joshi et al., 2009). Indeed, current cardiovascular
nuclear and echocardiographic imaging techniques affect out-
comes due to their ties with medical, percutaneous or surgical
interventions. Thus, considerable attention is being focused
on using CT to provide physiologic myocardial perfusion
information downstream from a stenosis, much like frac-
tional ﬂow reserve is used in the catheterization laboratory
or stress perfusion imaging in the nuclear, echocardiography
or cardiovascular MR laboratories (Ambrose, 2008). We
need functional as well as anatomic data to guide therapy.
In a different direction, CT (Cheng et al., 2009) CMR, and
other methods are being developed to better characterize
the nature of atherothrombotic plaque, the cause of both
ﬂow limiting stable coronary stenosis, and, when a plaque
ruptures or erodes, acute coronary occlusion and myocardial
infarction.
Crucial to this work is validation of the ability of non-inva-
sive imaging to delineate physiologically relevant structural
features of atherothrombotic plaque. Histology, the a priori
gold standard, is limited in its ability to characterize the eva-
nescent nature of the atherothrombotic process; post-mortem
examination of histologic sections represents only a limited
snapshot of the overall pathologic process. Nevertheless, these
ex vivo histologic observations do serve to remind us of the res-
olution of both 40 MHz ultrasound and 64-slice CT in failing
to depict the microstructure of plaque.
Several other methods for in vivo interrogation of athero-
thrombotic plaque promise new insights into the pathophysiol-
ogy of acute coronary syndromes, and could be superior not
only to intravascular ultrasound and 64-detector CT, but also
to conventional histologic analysis. Thermography, ﬂuores-
cence imaging, nuclear imaging, magnetic resonance imaging,optical coherence tomography and near-infrared spectroscopy
all have unique applications in detecting and characterizing
plaque (Cheng et al., 2009; Waxman et al., 2009). In these ef-
forts to detect and characterize plaque, it will be important to
integrate morphologic and rheologic information with a pa-
tient’s overall state of coagulation and inﬂammation. Imaging
will continue to play a central role in the investigation of the
atherothrombotic process and development of new treatments
for patients with coronary arterial disease. Adoption of any of
these techniques for clinical use in individual patients awaits
clinical trials in which plaque imaging is shown to lead to bet-
ter risk stratiﬁcation, identiﬁcation of manifest disease and
application or alteration of effective therapy (Matter and
Stuber, 2009).
Similar progress has also been made in applying new imag-
ing technology to valvular, myocardial and congenital heart
diseases. Ultrasound, nuclear imaging, magnetic resonance
and computed tomography have all grown enormously, both
in their contribution to our understanding of cardiovascular
disease and in their cost to the health care system. In many re-
gards, we have become victims of our own success. Patients
and referring physicians alike have come to expect that imag-
ing will be performed in nearly any circumstance, and many of
us have been seduced by spectacular cardiovascular images to
believe that imaging is an endpoint, in and of itself, rather than
a means to a more meaningful end – making patients feel bet-
ter, function better and live longer.
As cardiac imaging has become more complex and more
widely utilized, the costs of medical health care have risen dra-
matically. The costs of imaging have grown faster than other
areas of health care, faster than costs of non-medical services,
and faster than the economy has expanded, threatening our
ability as a society to pay for these wondrous imaging proce-
dures. While a picture may still be worth a thousand words,
there is now widespread recognition that unbridled expansion
of imaging services does not lead to better health. We have en-
tered an era when a beneﬁcial outcome must be documented
for nearly everything we do, so that we may make informed
decisions on how to spend our limited resources on health care
(Douglas et al., 2009).
We clinical imagers are now challenged not only to con-
tinue pursuing creative technical and engineering advances in
our imaging procedures, but to also steer these developments
toward improving patient outcomes. It is necessary but not
sufﬁcient to produce excellent quality images of the highest
technical quality; reporting the results accurately and
efﬁciently. We must also produce clinically actionable answers
to clinically actionable and relevant questions in ﬁscally
responsible and cost effective manner. We clinicians must lead
the charge to use imaging discriminately, using the right
procedure at the right time, for the right reason – the patients’
beneﬁt (Shaw et al., 2010; Bove, 2009; Hackbarth et al.,
2008).
Imaging has obvious value in detecting and identifying dis-
ease early in its course, and in directing appropriate and effec-
tive prevention and treatment. Imaging can help measure the
progression of disease, identifying ineffective treatments and
helping to identify newer and better treatments. Imaging is
increasingly an inseparable part of interventional cardiology
and cardiovascular surgery, helping plan and monitor treat-
ment, avoiding complications and deﬁning ‘‘success’’. Echo-
cardiographic equipment is no longer restricted to the
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the cardiac interventional laboratory and operating theater.
Computed tomography is no longer restricted to the radiology
department, but is integrated into the cath and nuclear labs,
the electrophysiology lab and the emergency room.
In this era of evidence-based medicine with emphasis on
‘‘real life’’ outcomes, we must show that an imaging procedure
produces new, non-redundant information which clinicians
can conﬁdently use to make meaningful decisions regarding
patient care, care that actually improves the patients well
being, functional status and longevity. The ideal imaging pro-
cedure would help improve patients’ quality of life by affecting
therapeutic choices and would be robust in diverse clinical
environments, not limited to highly specialized units. The test
should be deﬁnitive, not leading to further testing to resolve
uncertainty, nor to pursuit of unrelated, incidental ﬁndings
of uncertain clinical importance. The imaging procedure itself
should also have a better beneﬁt to risk ratio for a particular
patient. Radiation exposure, if any, should be monitored and
minimized. And having achieved all these lofty goals, an imag-
ing procedure should also be cost-effective, delivering value to
the individual and to society comparable to the value of other
goods and services.
We need to train new imaging physicians who are knowl-
edgeable in applying multiple imaging modalities to a given pa-
tient’s problem and to think critically in evaluating the
resulting information correctly into clinical decision making
(Kosiborod and Spertus, 2009). Not all new modalities and
new applications work as well in widespread clinical practice
as they do in small numbers of patients in specialized luminary
sites. To wit, use of tissue Doppler to select patients for cardiac
resynchronization and use of proximal isovelocity area mea-
surements to quantify the degree of mitral regurgitation turn
out to be poorly reproducible in the clinical setting and not
as useful in practice as was originally thought based on techni-
cal considerations and logic alone (Popovic and Thomas, 2008;
Biner et al., 2010). We also need to recognize that existing
‘‘gold standards’’ are not good enough, and not be satisﬁed
simply inventing new methods that produce results that resem-
ble existing data. For instance, intra-arterial coronary angiog-
raphy may be the existing gold standard for diagnosing
coronary artery disease, but assessing the degree of obstruction
by visual or even quantitative evaluation of angiograms, either
intra-arterial or by CTA, does not compare well with a better
gold standard – assessment of fractional ﬂow reserve (Tonino
et al., 2009; Schoepf et al., 2007).
Both we and our patients are enamored with technology.
Our expectations of advanced imaging technology do not al-
ways match the real value delivered. If we are to be able to af-
ford to offer truly useful imaging to our patients, we must be
willing to look at our offerings critically, eliminating waste,
duplication and unneeded testing. Cardiovascular imaging is
robust. We can withstand critical appraisal of our ﬁeld, and
will be strengthened by refocusing our efforts to use technol-
ogy in a more thoughtful manner. We have enjoyed almost
unbridled access to technologic improvements in cardiovascu-
lar imaging over the past 50 years. Future developments in
imaging need not be constrained by emphasis on evidence of
beneﬁcial outcomes if we stay focused on the patient. In the
words of Helen Keller, blind and deaf author, lecturer and so-
cial activist, ‘‘The only thing worse than being blind is having
sight but no vision’’.References
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